Search

Author/Creator Gilotti, Geralyn

1. International sentinel site surveillance of patients with transfusional hemosiderosis treated with deferasirox in actual practice setting. Issue 1 (1st January 2019)

Authors:
El-Beshlawy, Amal; Inusa, Baba; Beneitez Pastor, David; Xicoy, Blanca; Soledada Duran Nieto, Maria; Bruederle, Andreas; Azmon, Amin; Gilotti, Geralyn; Elalfy, Mohsen
Journal:
Hematology
Issue:
Volume 24:Issue 1(2019)
Page Start:
238
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Long‐term safety and efficacy of deferasirox in young pediatric patients with transfusional hemosiderosis: Results from a 5­year observational study (ENTRUST). Issue 9 (10th March 2017)

Authors:
Vichinsky, Elliott; El‐Beshlawy, Amal; Al Zoebie, Azzam; Kamdem, Annie; Koussa, Suzanne; Chotsampancharoen, Thirachit; Bruederle, Andreas; Gilotti, Geralyn; Han, Jackie; Elalfy, Mohsen
Journal:
Pediatric blood & cancer
Issue:
Volume 64:Issue 9(2017)
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study. Issue 7 (July 2022)

Authors:
Passamonti, Francesco; Palandri, Francesca; Saydam, Guray; Callum, Jeannie; Devos, Timothy; Guglielmelli, Paola; Vannucchi, Alessandro M; Zor, Evren; Zuurman, Mike; Gilotti, Geralyn; Zhang, Yifan; Griesshammer, Martin
Journal:
Lancet
Issue:
Volume 9:Issue 7(2022)
Page Start:
e480
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗